64 results
6-K
EX-10.1
BDRX
Biodexa Pharmaceuticals Plc
26 Apr 24
Current report (foreign)
8:45am
F-1/A
EX-10.26
BDRX
Biodexa Pharmaceuticals Plc
14 Dec 23
Registration statement (foreign) (amended)
5:20pm
6-K
EX-10.1
BDRX
Biodexa Pharmaceuticals Plc
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
EX-10.6
BDRX
Biodexa Pharmaceuticals Plc
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
EX-10.5
BDRX
Biodexa Pharmaceuticals Plc
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
EX-10.2
38j5wzuwg2zn7x0
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
EX-10.3
dpzmqmi2df b4ugd8
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
EX-10.4
dfwnv
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K/A
EX-10.1
n362t6ekiasjze9ta
25 May 23
Amendment No. 2
9:53pm
6-K/A
EX-10.3
vq0ags
25 May 23
Amendment No. 1
4:46pm
6-K/A
EX-10.4
qzqsyeu
25 May 23
Amendment No. 1
4:46pm
6-K/A
EX-10.1
vh0yylyn0
25 May 23
Amendment No. 1
4:46pm
6-K/A
EX-10.5
m15vst3
25 May 23
Amendment No. 1
4:46pm
6-K/A
EX-10.2
kzlpe
25 May 23
Amendment No. 1
4:46pm
6-K
EX-10.4
5fm1yxk7s sps4fys
24 May 23
Current report (foreign)
5:29pm
6-K
EX-10.2
cy112r i4e4ze
24 May 23
Current report (foreign)
5:29pm
6-K
EX-10.1
dghg2fmq127n il
24 May 23
Current report (foreign)
5:29pm
6-K
EX-10.3
po0xii1flx2e4qqu
24 May 23
Current report (foreign)
5:29pm
6-K
EX-10.5
ptb4pnj
24 May 23
Current report (foreign)
5:29pm
424B3
EX-10.2
plhj8s9c
9 Feb 23
Prospectus supplement
4:15pm